DexTech is a Swedish research company specialising in urological oncology, mainly within prostate cancer. DexTech develops candidate medications based on a modified carbon hydrate molecule combined with active substances, including generics. The company has a strong clinical base with valuable specialist competence from its research laboratory and production for clinical oncology.
Nylige resultater fra fase IIb OsteoDex:
The secondary endpoints of the study include overall survival studied by 24 months of post-treatment follow-up. Of the patients who responded to treatment, with deceleration or stabilization of the disease, the median survival has not yet been achieved (> 27 months), compared with 14 months for the other patients (significance, p <0.05). Survival 2 years after baseline is 65% for patients who responded to treatment, with deceleration or stabilization of the disease, compared with 28% for other patients (significance, p <0.05).
The results of the study are very positive and show that OsteoDex effectively slows down the tumour disease. Overall survival data should be seen as an indication, as these data need, for natural reasons, be confirmed in a significantly larger, so-called Phase III study.
The company’s intention is to sign a license agreement before the end of the current year.